TTC14

Across TCGA pan-cancer cohorts, TTC14 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TTC14 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TTC14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC14 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SCLC, and UCEC are the cancer types where TTC14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.052	0.686	<.001	19	view →
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
UCEC	DFS	Median	All	0.934	0.615	.008	14	view →
LGG	OS	Median	All	0.034	0.909	<.001	12	view →
PRAD	DFS	Median	All	0.115	0.776	<.001	12	view →
LIHC	DFS	Median	All	0.105	0.530	.003	6	view →
ESCA	OS	Median	II,III,IV	0.345	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TTC14–LUAD (DFS)

Open the LUAD breakdown →